Ionic Rare Earths Limited

IXR

Ionic Rare Earths Ltd. is a mineral exploration company. The company is headquartered in Perth, Western Australia and currently employs 34 full-time employees. The firm is focused on developing its flagship Makuutu Rare Earths Project (Makuutu) towards production. The Makuutu comprises approximately six licenses covering approximately 298 square kilometers (km2) and is located over 40 kilometers east of the regional center of Jinja and approximately 120 kilometers east of the capital city of Kampala in eastern Uganda. The Company, through Ionic Technologies International Limited, has developed rare earth element (REE) separation and refining technology and applied this to the recovery and separation of individual rare earths from spent permanent magnets. The Company’s exploration license includes EL00257, EL00147 and EL00148. Its wholly owned subsidiary is Goldcap Resources Pty Limited. Its wholly owned subsidiary includes Ionic Technologies International Limited.

Ixup Limited

IXU

IXUP Ltd. is a software company that is redefining the way organizations collaborate on vast amounts of data with its data collaboration and encryption platform. The company is headquartered in Sydney, New South Wales. The company went IPO on 2017-11-15. The firm has a suite of software products that facilitate the secure sharing and analysis of sensitive information using advanced security technology. Its Secure Data Collaboration Suite of products represents the missing key to organizations unlocking their information assets previously unable to be shared or commercialized due to concerns around privacy, cybersecurity, and compliance considerations. The company operates in three geographic segments: Australia, the UK, and the U.S. The company is also the developer and operator of BetStop - National Self Exclusion Register, under contract with the Commonwealth Government of Australia via the Australian Communications and Media Authority (ACMA). The IXUP platform uses homomorphic encryption at the cellular level and can run in-depth calculations and analysis on multiple data sets without ever needing to decrypt them. The IXUP preserves privacy by securing analytics with advanced encryption.

Invex Therapeutics Ltd

IXC

Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Perth, Western Australia. The company went IPO on 2019-07-05. The firm is focused on developing treatments for neurological conditions and focused on developing treatments for neurological conditions. Its primary focus is Idiopathic Intracranial Hypertension (IIH), a condition of predominately overweight women of childbearing age, which can lead to disabling headaches and, in some patients, permanent vision loss. The company has completed a Phase II trial. The Company’s lead program is the development of Presendin for IIH. Presendin is a once-per week, subcutaneous, sustained-release (SR) Exenatide microsphere formulation developed by Peptron, Inc. The firm is conducting a Phase III clinical trial (IIH EVOLVE) designed to meet the requirements for market approval of Presendin for the treatment of IIH in the European Union (EU), United Kingdom (UK) and Australia.

iShares Global Consumer Staples ETF

IXI

IXI.AX was created on 2006-09-12 by iShares. The fund's investment portfolio concentrates primarily on consumer staples equity. The fund aims to provide investors with the performance of the S&P Global 1200 Consumer Staples Sector Index, before fees and expenses. The index is designed to measure the performance of global consumer staples companies and may include large-, mid- or smallcapitalisation stocks.